- Coccidiosis has a substantial economic impact on the poultry industry with estimated annual losses exceeding US$15 billion globally and US$7 billion in Asia.
- Monimax® by Huvepharma combines monensin and nicarbazin, offering a synergistic effect that allows for lower dosages and reduces stress on birds.
- Monimax® has demonstrated its effectiveness in over 120 trials worldwide, including recent Southeast Asian tests. It significantly improves performance metrics such as daily weight gain and feed conversion rates, making it a valuable solution for regional poultry producers.
Huvepharma®, a global leader in coccidiosis management, announced the launch of Monimax® in Southeast Asia. To better understand the product features and its benefits to the regional market, Poultry & Meat Asia Magazine spoke with Ben Dehaeck and Leandro Ferreira from Huvepharma's technical team.
Why is coccidiosis control important to the poultry industry?
Despite being an old and well-known disease, coccidiosis remains one of the most important diseases for poultry production globally. The economic impact of coccidiosis in the world and Asia is estimated at over US$15 billion and US$7 billion per year, respectively.
Adequate control of coccidiosis is imperative for poultry farmers because suboptimal control leads to poor body weight and high feed conversion (FCR) while potentially driving an increased need for antimicrobials to treat intestinal problems for which coccidiosis is a trigger, such as dysbacteriosis and necrotic enteritis.
What is Monimax® and how is it different from other current solutions?
Monimax® is a unique microgranulated anticoccidial that combines monensin and nicarbazin in one granule. Huvepharma has spent many years and several million euros developing this product which provides the poultry industry with a reliable and flexible combination product.
Although other combinations are available, Huvepharma found that monensin and nicarbazin are ideal. The synergistic effect between monensin and nicarbazin in chickens was demonstrated in vivo and recently published in the scientific journal Avian Pathology. The combination allows them to be used in lower concentrations, and because high doses of nicarbazin can cause stress, the blend of the two in Monimax® lowers the risk of harm to birds.
Secondly, better coccidiosis control also improves litter quality which benefits foot pad lesions (birds' welfare). Monimax® is the only anticoccidial combination registered for use in broilers, pullets and turkeys. Its physical presentation, safety and efficacy make it an ideal solution for producers of multispecies feed.
What are the benefits of Monimax® on the global and Asian field challenges?
More than 120 trials have been conducted in Latin America, Africa, Europe and Asia, demonstrating that this combination effectively controls coccidiosis and improves performance.
Overall, Monimax® significantly reduces coccidiosis damage (lower lesion score), increases daily weight gain (DWG), and significantly lowers FCR compared with the main anticoccidial combinations in the market.
A recent series of anticoccidial sensitivity tests (AST), performed between 2022 and 2024 in Thailand, Vietnam, Malaysia and the Philippines, demonstrated Monimax®'s efficacy in controlling coccidiosis and improving performance.
Where is Monimax® available in Southeast Asia?
We recently secured the Monimax® registration in Malaysia and Indonesia after proving its efficacy in Europe and many other countries globally. The product has also been approved in the Philippines, Thailand and Vietnam.
